Compare ACCO & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | SGHT |
|---|---|---|
| Founded | 1893 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.1M | 395.5M |
| IPO Year | N/A | 2021 |
| Metric | ACCO | SGHT |
|---|---|---|
| Price | $3.79 | $7.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.00 | ★ $8.23 |
| AVG Volume (30 Days) | ★ 793.0K | 312.9K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,544,000,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.83 | $12.07 |
| P/E Ratio | $8.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $2.03 |
| 52 Week High | $5.68 | $9.24 |
| Indicator | ACCO | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 42.80 |
| Support Level | $3.63 | $7.28 |
| Resistance Level | $3.78 | $8.19 |
| Average True Range (ATR) | 0.08 | 0.58 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 62.96 | 10.07 |
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.